Early Diagnosis and Screening for Lung Cancer

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2021 May 18

PMID 34001525

Citations 15

Authors

Humam Kadara

Linh M Tran

Bin Liu

Anil Vachani

Shuo Li

Ansam Sinjab

Xianghong J Zhou

Steven M Dubinett

Kostyantyn Krysan

Affiliations

Soon will be listed here.

Abstract

Cancer interception refers to actively blocking the cancer development process by preventing progression of premalignancy to invasive disease. The rate-limiting steps for effective lung cancer interception are the incomplete understanding of the earliest molecular events associated with lung carcinogenesis, the lack of preclinical models of pulmonary premalignancy, and the challenge of developing highly sensitive and specific methods for early detection. Recent advances in cancer interception are facilitated by developments in next-generation sequencing, computational methodologies, as well as the renewed emphasis in precision medicine and immuno-oncology. This review summarizes the current state of knowledge in the areas of molecular abnormalities in lung cancer continuum, preclinical human models of lung cancer pathogenesis, and the advances in early lung cancer diagnostics.

Citing Articles

Development and validation of a tumor marker-based model for the prediction of lung cancer: an analysis of a multicenter retrospective study in Shanghai, China.

Hu S, Guo Q, Ye J, Ma H, Zhang M, Wang Y Front Oncol. 2024; 14:1427170.

PMID: 39544305 PMC: 11562644. DOI: 10.3389/fonc.2024.1427170.

Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.

Moghaddam S, Savai R, Salehi-Rad R, Sengupta S, Kammer M, Massion P Am J Respir Crit Care Med. 2024; 210(5):548-571.

PMID: 39115548 PMC: 11389570. DOI: 10.1164/rccm.202406-1168ST.

Machine Learning Model of ResNet50-Ensemble Voting for Malignant-Benign Small Pulmonary Nodule Classification on Computed Tomography Images.

Li W, Yu S, Yang R, Tian Y, Zhu T, Liu H Cancers (Basel). 2023; 15(22).

PMID: 38001677 PMC: 10670717. DOI: 10.3390/cancers15225417.

Serum Insights: Leveraging the Power of miRNA Profiling as an Early Diagnostic Tool for Non-Small Cell Lung Cancer.

Charkiewicz R, Sulewska A, Mroz R, Charkiewicz A, Naumnik W, Kraska M Cancers (Basel). 2023; 15(20).

PMID: 37894277 PMC: 10605272. DOI: 10.3390/cancers15204910.

The MAGE A1-A10 Expression associated with Histopathological Findings of Malignant or Non-Malignant Cells in Peripheral Lung Tumors.

Mastutik G, Rahniayu A, Marhana I, Kurniassari N, Rahaju A, Amin M Asian Pac J Cancer Prev. 2023; 24(7):2329-2335.

PMID: 37505763 PMC: 10676496. DOI: 10.31557/APJCP.2023.24.7.2329.

References

Peeters D, De Laere B, Van den Eynden G, Van Laere S, Rothe F, Ignatiadis M . Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer. 2013; 108(6):1358-67. PMC: 3619252. DOI: 10.1038/bjc.2013.92. View

Normanno N, Rossi A, Morabito A, Signoriello S, Bevilacqua S, Di Maio M . Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer. 2014; 85(2):314-9. DOI: 10.1016/j.lungcan.2014.05.002. View

Sivakumar S, San Lucas F, McDowell T, Lang W, Xu L, Fujimoto J . Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017; 77(22):6119-6130. PMC: 5774855. DOI: 10.1158/0008-5472.CAN-17-1605. View

Kolinsky M, Stoecklein N, Lambros M, Gil V, Nava Rodrigues D, Carreira S . Genetic Analysis of Circulating Tumour Cells. Recent Results Cancer Res. 2019; 215:57-76. DOI: 10.1007/978-3-030-26439-0_3. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Wistuba I, Lam S, Behrens C, Virmani A, Fong K, LERICHE J . Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997; 89(18):1366-73. PMC: 5193483. DOI: 10.1093/jnci/89.18.1366. View

Delgado O, Kaisani A, Spinola M, Xie X, Batten K, Minna J . Multipotent capacity of immortalized human bronchial epithelial cells. PLoS One. 2011; 6(7):e22023. PMC: 3131301. DOI: 10.1371/journal.pone.0022023. View

Balsara B, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H . Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004; 25(11):2053-9. DOI: 10.1093/carcin/bgh226. View

Hamilton G, Burghuber O, Zeillinger R . Circulating tumor cells in small cell lung cancer: ex vivo expansion. Lung. 2015; 193(3):451-2. DOI: 10.1007/s00408-015-9725-7. View

10.

Tichelaar J, Zhang Y, Leriche J, Biddinger P, Lam S, Anderson M . Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer. 2005; 5:155. PMC: 1325242. DOI: 10.1186/1471-2407-5-155. View

11.

Westra W . Early glandular neoplasia of the lung. Respir Res. 2001; 1(3):163-9. PMC: 59555. DOI: 10.1186/rr28. View

12.

Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G . Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019; 571(7766):570-575. DOI: 10.1038/s41586-019-1330-0. View

13.

Sato M, Larsen J, Lee W, Sun H, Shames D, Dalvi M . Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013; 11(6):638-50. PMC: 3687022. DOI: 10.1158/1541-7786.MCR-12-0634-T. View

14.

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

15.

Eyer K, Doineau R, Castrillon C, Briseno-Roa L, Menrath V, Mottet G . Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring. Nat Biotechnol. 2017; 35(10):977-982. DOI: 10.1038/nbt.3964. View

16.

Krysan K, Tran L, Grimes B, Fishbein G, Seki A, Gardner B . The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. Cancer Res. 2019; 79(19):5022-5033. PMC: 6774823. DOI: 10.1158/0008-5472.CAN-19-0153. View

17.

Tammemagi M, Schmidt H, Martel S, McWilliams A, Goffin J, Johnston M . Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 2017; 18(11):1523-1531. DOI: 10.1016/S1470-2045(17)30597-1. View

18.

Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang T . Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer. 2011; 104(9):1410-7. PMC: 3101944. DOI: 10.1038/bjc.2011.94. View

19.

Punnoose E, Atwal S, Liu W, Raja R, Fine B, Hughes B . Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012; 18(8):2391-401. DOI: 10.1158/1078-0432.CCR-11-3148. View

20.

Muinelo-Romay L, Vieito M, Abalo A, Nocelo M, Baron F, Anido U . Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment. Cancers (Basel). 2014; 6(1):153-65. PMC: 3980598. DOI: 10.3390/cancers6010153. View